# Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide

> **NCT06497595** · NA · NOT_YET_RECRUITING · sponsor: **Sheba Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus in Obese

## Interventions

- **BEHAVIORAL:** Wegovy (2.4 Mg Dose) + exercise & nutrition
- **OTHER:** Wegovy (2.4 Mg Dose) + usual care

## Key facts

- **NCT ID:** NCT06497595
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06497595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06497595, "Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06497595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*